查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1698085

腎癌藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依治療類別、藥理類別、地區及競爭情形分類，2020-2030 年預測）

Kidney Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Pharmacologic Class, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球腎癌藥物市場價值為 71.5 億美元，預計在預測期內將呈現強勁成長，到 2030 年的複合年成長率為 6.45%。腎癌，也稱為腎細胞癌，是一種起源於腎臟的癌症，腎臟是一種豆形器官，負責過濾血液中的廢物和多餘的液體以形成尿液。腎癌，醫學上稱為腎細胞癌 (RCC)，是一種複雜且具有挑戰性的疾病，需要有效的治療策略。隨著醫學研究的進步和藥物創新的加速，幾個關鍵促進因素正在推動腎癌藥物市場的成長和發展。標靶治療是一類旨在抑制對癌細胞生長和存活至關重要的特定分子或途徑的藥物。對於腎臟癌而言，標靶治療徹底改變了治療方法。例子包括酪胺酸激酶抑制劑 (TKI)，如舒尼替尼、帕唑帕尼和阿昔替尼。這些藥物會破壞促進腫瘤生長和血管生成（新血管形成）的訊號路徑。這些藥物的引入極大地改變了腎癌治療的模式。曾經面臨有限選擇的患者現在可以獲得一系列可提高生存率和生活品質的治療方法。隨著研究的不斷深入，腎癌藥物市場將迎來進一步的發展。聯合療法、個人化醫療方法以及新目標的整合即將出現。此外，研究人員、製藥公司、醫療保健組織和患者權益團體之間的持續合作將繼續影響創新療法的發展，並最終為腎癌患者帶來更好的治療效果。

市場概覽
預測期 2026-2030
2024 年市場規模 71.5 億美元
2030年市場規模 104.3 億美元
2025-2030 年複合年成長率 6.45％
成長最快的領域 標靶治療
最大的市場 北美洲

主要市場促進因素

腎癌發生率上升

主要市場挑戰

抗藥性和治療異質性

主要市場趨勢

個人化醫療革命

目錄

第 1 章：產品概述

第 2 章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球腎癌藥物市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類別（標靶治療、免疫療法、化療）
    • 依藥理類別（血管新生抑制劑、單株抗體、mTOR 抑制劑、細胞激素免疫療法 (IL-2)）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第6章：北美腎癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第7章：歐洲腎癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太腎癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美腎癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲腎癌藥物市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章： 大環境分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Genentech Inc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Exelixis Inc
  • Prometheus Laboratories Inc
  • Glaxosmithkline PLC.
  • F. Hoffmann-LA Roche AG

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 17209

Global Kidney Cancer Drugs Market was valued at USD 7.15 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.45% through 2030. Kidney cancer, also known as renal cell carcinoma, is a type of cancer that originates in the kidneys, the bean-shaped organs responsible for filtering waste and excess fluids from the blood to form urine. Kidney cancer, medically termed renal cell carcinoma (RCC), is a complex and challenging disease that demands effective treatment strategies. As medical research advances and pharmaceutical innovation accelerates, several key drivers are propelling the growth and evolution of the kidney cancer drugs market. Targeted therapies are a class of drugs designed to inhibit specific molecules or pathways that are crucial for cancer cell growth and survival. In kidney cancer, targeted therapies have revolutionized treatment. Examples include tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and axitinib. These drugs disrupt the signaling pathways that promote tumor growth and angiogenesis (formation of new blood vessels). The landscape of kidney cancer treatment has been dramatically transformed by the introduction of these drugs. Patients who once faced limited options now have access to a range of therapies that offer improved survival rates and enhanced quality of life. As research continues, the kidney cancer drugs market is poised for further advancements. Combination therapies, personalized medicine approaches, and the integration of novel targets are on the horizon. Additionally, the ongoing collaboration among researchers, pharmaceutical companies, healthcare organizations, and patient advocacy groups will continue to shape the development of innovative therapies and ultimately lead to better outcomes for patients facing kidney cancer.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.15 Billion
Market Size 2030USD 10.43 Billion
CAGR 2025-20306.45%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Kidney Cancer

The global kidney cancer market is experiencing significant expansion, largely driven by the rising incidence of kidney cancer worldwide. In 2022, kidney cancer accounted for 434,840 newly diagnosed cases globally, making it the 14th most prevalent cancer worldwide. It ranked as the 10th most diagnosed cancer among men and the 13th among women, underscoring its significant impact on global healthcare systems and oncology markets. The increasing number of renal cell carcinoma (RCC) cases-the most common type of kidney cancer-has created a growing demand for advanced diagnostics, innovative therapeutics, and improved healthcare infrastructure. This trend is not only shaping market dynamics but also influencing the strategic direction of pharmaceutical companies, healthcare providers, and investors. The global population is aging at an unprecedented rate. Between 1974 and 2024, the proportion of individuals aged 65 and older nearly doubled, rising from 5.5% to 10.3%, and age is a significant risk factor for kidney cancer. With higher life expectancy, the number of kidney cancer cases is expected to increase, driving demand for effective treatment options. Developed regions such as North America and Europe report higher incidence rates due to advanced screening programs and improved diagnostic capabilities. Meanwhile, emerging economies in Asia-Pacific are seeing rising cases due to lifestyle changes and increasing industrialization, leading to a higher demand for cancer therapeutics.

Key Market Challenges

Resistance and Treatment Heterogeneity

Despite the advancements in targeted therapies and immunotherapies, the development of resistance to these treatments remains a significant challenge in kidney cancer. Over time, tumors can evolve and adapt, rendering once-effective therapies ineffective. This challenge underscores the need for continuous research to understand the mechanisms of resistance and develop strategies to overcome it. Additionally, kidney cancer is not a homogeneous disease. Different subtypes and genetic variations contribute to variations in treatment response. Developing therapies that are effective across diverse patient populations is a complex endeavor that requires a deep understanding of tumor biology and personalized medicine approaches.

Key Market Trends

Personalized Medicine Revolution

The era of personalized medicine has dawned upon the field of kidney cancer treatment, offering immense promise for improved patient outcomes. With the advent of precision oncology, the one-size-fits-all approach to treatment is giving way to tailored interventions that account for individual genetic profiles and biomarker expression. Advancements in genomics and molecular diagnostics enable oncologists to identify specific genetic mutations or alterations driving a patient's kidney cancer. Armed with this information, they can prescribe targeted therapies that are more likely to elicit a favorable response. This shift towards personalized treatment approaches not only enhances the efficacy of drugs but also minimizes the potential for adverse effects.

Key Market Players

  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • Genentech Inc.
  • Bristol-Myers Squibb
  • Eisai Co., Ltd.
  • Exelixis Inc
  • Prometheus Laboratories Inc
  • Glaxosmithkline PLC.
  • F. Hoffmann-LA Roche AG

Report Scope:

In this report, the Global Kidney Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Kidney Cancer Drugs Market, By Therapeutic Class:

  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

Kidney Cancer Drugs Market, By Pharmacologic Class:

  • Angiogenesis Inhibitors
  • Monoclonal Antibodies
  • mTOR Inhibitors
  • Cytokine Immunotherapy (IL-2)

Kidney Cancer Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Kidney Cancer Drugs Market.

Available Customizations:

Global Kidney Cancer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Kidney Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Class (Targeted Therapy, Immunotherapy, Chemotherapy)
    • 5.2.2. By Pharmacologic Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy (IL-2))
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Kidney Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Class
    • 6.2.2. By Pharmacologic Class
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Kidney Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Class
        • 6.3.1.2.2. By Pharmacologic Class
    • 6.3.2. Mexico Kidney Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Class
        • 6.3.2.2.2. By Pharmacologic Class
    • 6.3.3. Canada Kidney Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Class
        • 6.3.3.2.2. By Pharmacologic Class

7. Europe Kidney Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Class
    • 7.2.2. By Pharmacologic Class
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Kidney Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Class
        • 7.3.1.2.2. By Pharmacologic Class
    • 7.3.2. Germany Kidney Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Class
        • 7.3.2.2.2. By Pharmacologic Class
    • 7.3.3. United Kingdom Kidney Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Class
        • 7.3.3.2.2. By Pharmacologic Class
    • 7.3.4. Italy Kidney Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Class
        • 7.3.4.2.2. By Pharmacologic Class
    • 7.3.5. Spain Kidney Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Class
        • 7.3.5.2.2. By Pharmacologic Class

8. Asia-Pacific Kidney Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Class
    • 8.2.2. By Pharmacologic Class
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Kidney Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Class
        • 8.3.1.2.2. By Pharmacologic Class
    • 8.3.2. India Kidney Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Class
        • 8.3.2.2.2. By Pharmacologic Class
    • 8.3.3. South Korea Kidney Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Class
        • 8.3.3.2.2. By Pharmacologic Class
    • 8.3.4. Japan Kidney Cancer Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Class
        • 8.3.4.2.2. By Pharmacologic Class
    • 8.3.5. Australia Kidney Cancer Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Class
        • 8.3.5.2.2. By Pharmacologic Class

9. South America Kidney Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Class
    • 9.2.2. By Pharmacologic Class
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Kidney Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Class
        • 9.3.1.2.2. By Pharmacologic Class
    • 9.3.2. Argentina Kidney Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Class
        • 9.3.2.2.2. By Pharmacologic Class
    • 9.3.3. Colombia Kidney Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Class
        • 9.3.3.2.2. By Pharmacologic Class

10. Middle East and Africa Kidney Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Class
    • 10.2.2. By Pharmacologic Class
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Kidney Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Class
        • 10.3.1.2.2. By Pharmacologic Class
    • 10.3.2. Saudi Arabia Kidney Cancer Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Class
        • 10.3.2.2.2. By Pharmacologic Class
    • 10.3.3. UAE Kidney Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Class
        • 10.3.3.2.2. By Pharmacologic Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Product & Service Offerings
    • 15.1.3. Recent Developments
    • 15.1.4. Financials (If Listed)
    • 15.1.5. Key Personnel
    • 15.1.6. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Bayer AG
  • 15.4. Genentech Inc.
  • 15.5. Bristol-Myers Squibb
  • 15.6. Eisai Co., Ltd.
  • 15.7. Exelixis Inc
  • 15.8. Prometheus Laboratories Inc
  • 15.9. Glaxosmithkline PLC.
  • 15.10. F. Hoffmann-LA Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer